Clinical Trials

A Study of PRT2527 in Participants With Advanced Solid Tumors

NCT05159518

Description of the Study

This is a Phase 1 dose-escalation and confirmation study of PRT2527, a Cyclin-dependent Kinase 9 (CDK9) inhibitor, in participants with advanced solid tumors. The purpose of this study is to define the dosing schedule, and maximally tolerated dose to be used in subsequent development of PRT2527.

Eligibility: